[go: up one dir, main page]

AR127728A1 - Nueva proteína de fusión específica para ox40 y pd-l1 - Google Patents

Nueva proteína de fusión específica para ox40 y pd-l1

Info

Publication number
AR127728A1
AR127728A1 ARP220103195A ARP220103195A AR127728A1 AR 127728 A1 AR127728 A1 AR 127728A1 AR P220103195 A ARP220103195 A AR P220103195A AR P220103195 A ARP220103195 A AR P220103195A AR 127728 A1 AR127728 A1 AR 127728A1
Authority
AR
Argentina
Prior art keywords
fusion proteins
proteins
fusion protein
protein specific
new fusion
Prior art date
Application number
ARP220103195A
Other languages
English (en)
Inventor
Marina Pavlidou
Kastresana Aizea Morales
Karoline Utschick
Benjamin Weiche
Lucia Pattarini
Catherine Gallou-Harnois
Original Assignee
Pieris Pharmaceuticals Gmbh
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh, Servier Lab filed Critical Pieris Pharmaceuticals Gmbh
Publication of AR127728A1 publication Critical patent/AR127728A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La descripción proporciona proteínas de fusión específicas tanto para OX40 como para PD-L1, en donde dichas proteínas pueden ser utilizadas para coestimular la activación de linfocitos de una manera dependiente de la diana PD-L1. Dichas proteínas de fusión pueden ser utilizadas en muchas aplicaciones farmacéuticas, por ejemplo como agentes anticáncer y/o moduladores inmunitarios. La presente descripción también se relaciona con métodos de preparación de las proteínas de fusión descriptas en la presente, así como con composiciones que comprenden dichas proteínas de fusión. La presente descripción se relaciona adicionalmente con moléculas de ácido nucleico que codifican dichas proteínas de fusión. Además, la solicitud describe usos terapéuticos y/o diagnóstico de dichas proteínas.
ARP220103195A 2021-11-19 2022-11-18 Nueva proteína de fusión específica para ox40 y pd-l1 AR127728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21306614 2021-11-19

Publications (1)

Publication Number Publication Date
AR127728A1 true AR127728A1 (es) 2024-02-21

Family

ID=78821243

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103195A AR127728A1 (es) 2021-11-19 2022-11-18 Nueva proteína de fusión específica para ox40 y pd-l1

Country Status (3)

Country Link
AR (1) AR127728A1 (es)
TW (1) TW202334203A (es)
WO (1) WO2023089079A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US10927154B2 (en) * 2014-01-13 2021-02-23 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
AU2017207318B2 (en) * 2016-01-11 2023-12-07 Inhibrx Biosciences, Inc. Multivalent and multispecific OX40-binding fusion proteins
CN111344019B (zh) * 2017-12-29 2024-03-15 圆祥生技股份有限公司 调节免疫检查点作为癌症治疗的单特异性与双特异性蛋白质
JP2022553176A (ja) * 2019-10-17 2022-12-22 江蘇康寧杰瑞生物制薬有限公司 Ｏｘ４０／ｐｄ－ｌ１二重特異性抗体

Also Published As

Publication number Publication date
TW202334203A (zh) 2023-09-01
WO2023089079A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
MX2021000401A (es) Nuevas proteinas de fusion especificas para cd137 y pd-l1.
MX2021010039A (es) Novedosas proteinas de fusion especificas para cd137 y gpc3.
Freyermuth-Trujillo et al. Inflammation: a target for treatment in spinal cord injury
BR112022014623A2 (pt) Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
MX390894B (es) Polipéptido de fusión anti-cáncer.
EP4378962A3 (en) Anti-cancer fusion polypeptide
MX2020011257A (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
BR112018016281A2 (pt) molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo
BR112013019975A2 (pt) proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
CO2020000369A2 (es) Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos
MX2019014397A (es) Polipeptidos que enlazan adamts5, mmp13 y agrecano.
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
MX2021000421A (es) Métodos y composiciones que usan células dendríticas recombinantes para el tratamiento del cáncer.
AR112069A1 (es) Inmunoglobulinas que fijan aggrecan
MX2019014448A (es) Inmunoglobulinas de enlace a mmp13.
BR112018017174A2 (pt) conjugados de aminoácido e peptídeo e processo de conjugação
BR112022008201A2 (pt) Degradação de proteínas de superfície usando agente de ligação biespecífico
CO2025003722A2 (es) Nueva proteína de fusión específica para cd137 y cd228
ZA202403355B (en) Single domain antibodies binding to tetanus neurotoxin
AR127728A1 (es) Nueva proteína de fusión específica para ox40 y pd-l1
BR112023022319A2 (pt) Anticorpos anti-tigit, anticorpos anti-cd96 e métodos de uso dos mesmos

Legal Events

Date Code Title Description
FB Suspension of granting procedure